Cyrille Stephane Kounde

Cyrille Stephane Kounde

Auto-generated profile, based on publicly available information

Cyrille Stephane Kounde

Department of Chemistry, Imperial College London, London, W12 0BZ, UK

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2020 in ACS Chemical Biology
Verified
Journal Article
Open access
MMMarı́a Maneiro
Marı́a Maneiro
NFNafsika Forte
Nafsika Forte
MSMaria M. Shchepinova
Maria M. Shchepinova
CKCyrille S. Kounde
Cyrille S. Kounde
VCVijay Chudasama
Vijay Chudasama
ETEdward W. Tate
Edward W. Tate
Targeting protein degradation with Proteolysis-Targeting Chimeras (PROTACs) is an area of great current interest in drug discovery. Nevertheless, although the high effectiveness of PROTACs against a wide variety of targets has been established, most degraders reported to date display limited intrinsic tissue selectivity, and do not discriminate between cells of different types. Here we describe a strategy for selec-tive protein degradation in a specific cell type. We report the design and synthesis of a trastuzumab-PROTAC conjugate (Ab PROTAC 3) in which E3 ligase-directed degrader activity is caged with an antibody linker which can be hydrolyzed following antibody-PROTAC internal-ization, releasing the active PROTAC and inducing catalytic protein degradation. We show that 3 selectively targets bromodomain-containing protein 4 (BRD4) for degradation only in HER2 positive breast cancer cell lines, whilst sparing HER2 negative cells. Using live cell confocal microscopy, we show internalization and lysosomal trafficking of the conjugate specifically in HER2 positive cells, leading to release of active PROTAC in quantities sufficient to induce potent BRD4 degradation. These studies demonstrate proof-of-concept for tissue-specific BRD4 degradation, overcoming limitations of PROTAC selectivity, with significant potential for application to novel targets.

3 April 2020 in Chemical Communications
Verified
Journal Article
Open access
PDF file
CKCyrille Stephane Kounde
Cyrille Stephane Kounde
MSMaria M. Shchepinova
Maria M. Shchepinova
CSCharlie N. Saunders
Charlie N. Saunders
MMMarcel X. Muelbaier
Marcel X. Muelbaier
MRMark D. Rackham
Mark D. Rackham
ETEdward William Tate
Edward William Tate
Caging of a widely used Von Hippel Lindau E3 ligase ligand for targeted protein degradation with PROTACs allows light-activated proteolysis.

3 February 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
SMStephanie Anne Moquin
Stephanie Anne Moquin
OSOliver Simon
Oliver Simon
RKRatna Karuna
Ratna Karuna
SLSuresh B. Lakshminarayana
Suresh B. Lakshminarayana
FYFumiaki Yokokawa
Fumiaki Yokokawa
FGFeng Gu
Feng Gu
NITD-688, a pan-serotype dengue virus inhibitor, is effective in mice and is well tolerated with favorable pharmacokinetics in animal models.

1 September 2022 in Chemical Communications
Verified
Journal Article
Open access
PDF file
QZQisi Zhang
Qisi Zhang
CKCyrille S. Kounde
Cyrille S. Kounde
MMMilon Mondal
Milon Mondal
JGJake L. Greenfield
Jake L. Greenfield
JBJennifer Baker
Jennifer Baker
ETEdward W. Tate
Edward W. Tate
A new class of arylazopyrazole photoswitchable PROTACs (AP-PROTACs) enables light-triggered degradation of a specific ensemble of protein kinases.

1 March 2017 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
CKCyrille S. Kounde
Cyrille S. Kounde
HYHui-Quan Yeo
Hui-Quan Yeo
QWQing-Yin Wang
Qing-Yin Wang
KWKah Fei Wan
Kah Fei Wan
HDHongping Dong
Hongping Dong
FYFumiaki Yokokawa
Fumiaki Yokokawa

23 November 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CKCyrille S. Kounde
Cyrille S. Kounde
ETEdward W. Tate
Edward W. Tate